Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 675 of 2228 entries
View as:

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Phase: N/A Priority: Normal
NCT ID: NCT04566601 Org: User:
Start: 11/13/20 End: 01/25/23 Due: 01/25/24

Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03047031 Org: User:
Start: 04/05/17 End: 07/21/22 Due: 07/21/23

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02758171 Org: User:
Start: 05/17/16 End: 08/03/16 Due: 08/03/17

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine

Phase: N/A Priority: Normal
NCT ID: NCT00002381 Org: User:
Start: - End: - Due: -

Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

Phase: N/A Priority: Normal
NCT ID: NCT00615992 Org: User:
Start: 04/30/07 End: - Due: -

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00275457 Org: User:
Start: 10/31/02 End: 04/30/04 Due: 04/30/05

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Phase: N/A Priority: Normal
NCT ID: NCT02249403 Org: User:
Start: 01/31/99 End: - Due: -

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Phase: N/A Priority: Normal
NCT ID: NCT05945888 Org: User:
Start: 07/25/23 End: 11/13/23 Due: 11/13/24

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Phase: N/A Priority: Normal
NCT ID: NCT00328172 Org: User:
Start: 05/31/06 End: - Due: -

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Phase: N/A Priority: Normal
NCT ID: NCT00560508 Org: User:
Start: 11/30/07 End: - Due: -

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00281593 Org: User:
Start: 04/30/06 End: - Due: -

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02121509 Org: User:
Start: 05/31/14 End: 07/31/14 Due: 07/31/15

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02191891 Org: User:
Start: 10/21/14 End: 04/18/18 Due: 04/18/19

Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse

Phase: N/A Priority: Normal
NCT ID: NCT02194153 Org: User:
Start: 05/31/01 End: - Due: -

Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02183090 Org: User:
Start: 11/30/98 End: - Due: -

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05882058 Org: User:
Start: 10/13/23 End: 07/30/27 Due: 07/30/28

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Phase: N/A Priority: Normal
NCT ID: NCT05879978 Org: User:
Start: 07/28/23 End: 09/05/25 Due: 09/05/26

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT04002310 Org: User:
Start: 07/26/19 End: 08/09/22 Due: 08/09/23

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

Phase: N/A Priority: Normal
NCT ID: NCT00793793 Org: User:
Start: 09/30/07 End: 01/25/11 Due: 01/25/12

Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)

Phase: N/A Priority: Normal
NCT ID: NCT02720757 Org: User:
Start: 08/26/16 End: 12/14/17 Due: 12/14/18

Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)

Phase: N/A Priority: Normal
NCT ID: NCT00292435 Org: User:
Start: 03/31/06 End: - Due: -

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02254031 Org: User:
Start: 07/01/03 End: - Due: -

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Phase: N/A Priority: Normal
NCT ID: NCT01830127 Org: User:
Start: 04/30/13 End: 10/31/14 Due: 10/31/15

This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

Phase: N/A Priority: Normal
NCT ID: NCT03604445 Org: User:
Start: 08/08/18 End: 07/27/22 Due: 07/27/23

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase: N/A Priority: Normal
NCT ID: NCT02244242 Org: User:
Start: 07/31/98 End: - Due: -